{"id":55780,"date":"2026-01-29T16:22:18","date_gmt":"2026-01-29T08:22:18","guid":{"rendered":"https:\/\/flcube.com\/?p=55780"},"modified":"2026-01-29T16:22:19","modified_gmt":"2026-01-29T08:22:19","slug":"danaher-q4-revenue-grows-3-to-24-6b-on-biotech-and-diagnostics-innovation","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55780","title":{"rendered":"Danaher Q4 Revenue Grows 3% to $24.6B on Biotech and Diagnostics Innovation"},"content":{"rendered":"\n

Danaher Corporation<\/strong> (NYSE:\u202fDHR<\/a>) reported fourth\u2011quarter and full\u2011year 2025 earnings with global revenues rising 3% year\u2011on\u2011year (YOY)<\/strong> to $24.6\u202fbillion<\/strong> , while core revenues grew 2% YOY<\/strong> . Net profit reached $3.6\u202fbillion<\/strong> . The company launched several innovative products across its life sciences and diagnostics segments during the year.<\/p>\n\n\n\n

Financial Performance Summary<\/h2>\n\n\n\n
Metric<\/th>Result<\/th><\/tr><\/thead>
Q4\/FY 2025 Revenue<\/strong><\/td>$24.6\u202fbillion<\/td><\/tr>
YOY Growth<\/strong><\/td>+3%<\/td><\/tr>
Core Revenue Growth<\/strong><\/td>+2% YOY<\/td><\/tr>
Net Profit<\/strong><\/td>$3.6\u202fbillion<\/td><\/tr>
Key Growth Drivers<\/strong><\/td>Bioprocessing, diagnostics menu expansion, mass spectrometry<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Innovations & Segment Highlights<\/h2>\n\n\n\n

Life Sciences<\/strong><\/h3>\n\n\n\n